Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)

Current Assets

Eli Lilly Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) increased by 190.1% to $9.79B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 190.6%, from $3.37B to $9.79B. Over 4 years (FY 2020 to FY 2024), Total Cash, Cash Equivalents, and Restricted Cash (Inclusive) shows a downward trend with a -2.8% CAGR.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2018
Last reportedQ3 2025
Metric ID: cash_and_equivalents_total_inclusive

Historical Data

18 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25
Value$3.22B$3.79B$3.82B$2.46B$2.62B$2.62B$2.07B$3.55B$2.69B$2.38B$2.82B$2.46B$3.22B$3.37B$3.27B$3.09B$3.38B$9.79B
QoQ Change—+17.6%+0.8%-35.6%+6.7%-0.2%-21.0%+71.5%-24.0%-11.6%+18.4%-12.7%+31.0%+4.5%-3.0%-5.4%+9.1%+190.1%
YoY Change————-18.5%-30.9%-45.9%+44.2%+2.7%-9.0%+36.4%-30.6%+19.6%+41.5%+16.0%+25.7%+4.7%+190.6%
Range$2.07B – $9.79B
CAGR+29.9%
Avg YoY Growth+17.6%
Median YoY Growth+10.3%
Current Streak2 quarters growth

Frequently Asked Questions

What is Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive)?
Eli Lilly (LLY) reported total cash, cash equivalents, and restricted cash (inclusive) of $9.79B in Q3 2025.
How has Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive) changed year-over-year?
Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive) increased by 190.6% year-over-year, from $3.37B to $9.79B.
What is the long-term trend for Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive)?
Over 4 years (2020 to 2024), Eli Lilly's total cash, cash equivalents, and restricted cash (inclusive) has grown at a -2.8% compound annual growth rate (CAGR), from $3.66B to $3.27B.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.